Hisamitsu Pharmaceutical Co Inc (Hisamitsu Pharmaceutical) manufactures and supplies pharmaceuticals, quasi drugs, and medical devices. The company operates through one reportable segment including research, development, manufacturing, and sale of pharmaceuticals. The company business is sub classifies into three segments namely, RX Business, OTC Business and Other Businesses. Hisamitsu Pharmaceutical’s products are based on transdermal drug delivery system (TDDS), which enables the APIs to permeate the skin on application.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company conducts R&D of transdermal drug delivery system (TDDS) products for a wide range of the therapeutic areas. Its R&D activities are focused on advancing its pipeline drugs and create new drugs and new drug formulations. The company also focuses on developing new over the counter (OTC) pharmaceuticals in Japan and overseas. The company’s pipeline products include HP-3150, an analgesic transdermal drug indicated for the treatment of low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis; HP-5070, a transdermal patch has filed for the treatment of primary palmar hyperhidrosis; and HP-5000 in Phase III trials indicated for treatment of osteoarthritis of the knee. Xelstrym (ATS) has been approved recently for the treatment of Attention Deficit, Hyperactivity Disorder(ADHD). Hisamitsu Pharmaceutical conducts its R&D activities at four major centers in Tosu, Tokyo, and Tsukuba in Japan; and in the US. The company conducts analytical testing, and technology transfer at Tosu laboratories. It carries out clinical development and R&D activities at Tokyo. Hisamitsu Pharmaceutical develops TDDS based products and conducts safety studies at Tsukuba laboratories. Through its subsidiary, Noven Pharmaceuticals Inc, the company advances its pipeline products in various clinical phases in the US. In FY2023, the company spent JPY9,785 million on its R&D activities.